Kardigan Inc 2026年季度报告

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the quarterly period ended June 30, 2026OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the transition period from _________________ to _________________Commission File Number: 001-43354 Kardigan, Inc.(Exact Name of Registrant as Specified in its Charter) 93-2994203(I.R.S. EmployerIdentification No.) Delaware( State or other jurisdiction ofincorporation or organization)506 Carnegie Center Drive, Suite 201Princeton, NJ(Address of principal executive offices) Registrant’s telephone number, including area code: (415) 573-3220 Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) hasbeen subject to such filing requirements for the past 90 days.Yes☐No☒ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was requiredto submit such files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and“emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Non-accelerated filer☒Emerging growth company☒ Accelerated filer☐Smaller reporting company☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ As of August 7, 2026, the registrant had 93,503,699 shares of common stock, $0.00001 par value per share, outstanding. Table of Contents PART I.FINANCIAL INFORMATION Item 1.Condensed Consolidated Financial Statements (Unaudited)4Condensed Consolidated Balance Sheets4Condensed Consolidated Statements of Operations and Comprehensive Loss5Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity(Deficit)6Condensed Consolidated Statements of Cash Flows7Notes to Condensed Consolidated Financial Statements8Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations41Item 3.Quantitative and Qualitative Disclosures About Market Risk55Item 4.Controls and Procedures55 PART II.OTHER INFORMATION Item 1.Legal Proceedings57Item 1A.Risk Factors58Item 2.Unregistered Sales of Equity Securities and Use of Proceeds132Item 3.Defaults Upon Senior Securities133Item 4.Mine Safety Disclosures133Item 5.Other Information133Item 6.Exhibits133Signatures135 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (“Quarterly Report”), of Kardigan, Inc. (the “Company”) contains or incorporates statementsthat constitute forward-looking statements within the meaning of the federal securities laws. Our forward-looking statementsinclude, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions orstrategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of futureevents or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,”“contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,”“project,” “should,” “will,” “would” and similar expressions may identify forward-looking statements, but the absence of thesewords does not mean that a statement is not forward-looking. Forward-looking statements in this Quarterly Report on Form 10-Qmay include, for example, statements about: •the initiation, timing, progress and results of our research and development programs, preclinical studies and clinical trials;•the anticipated timing of release of topline data from the ongoing Phase 2b Cohort 1 trial of Danicamtiv KINSHIP-DCM,the ongoing Phase 2b clinical trial of KATALYST-AV, and the ongoing KARDINAL-ASH Phase 2 clinical trial;•the ability of clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results, and theability of our preclinical studies to predict later clinical trial results;•the timing, scope and likelihood of regulatory filings and ap